USCOM LIMITED — Regulatory Filings 2012

Sep 23, 2012

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

Role for USCOM in cancer treatment

Monday 24th of September 2012: Uscom (ASX code: UCM).

Uscom Ltd today announced the publication of independent research confirming the effectiveness of USCOM cardiac monitoring during cancer treatment. The research was performed collaboratively by researchers from the Medical Department and the Institute of Clinical Chemistry, at the Ludwig-Maximilians University of Munich, Germany and was published in the Cancer Journal Onkologie.

Dr Geiger and her colleagues studied 50 patients being treated for various kinds of cancers with drugs which may be complicated by cardiac damage. They compared results using the current more expensive and time consuming method with those from USCOM and found “ Combining…. USCOM and serum biomarkers is feasible for monitoring the immediate and chronic hemodynamic changes during an anthracycline based regimen. ” They concluded that “The role of USCOM is evolving in intensive care medicine. In our opinion this technique deserves closer attention in the cardiac monitoring of cancer patient populations.” The research recommended further study of USCOM in the fields of hematology and oncology.

A number of drugs can be used to reduce the growth of the cancers. However these same drugs can damage the heart, so early detection of changes in heart function allows changes in treatment to limit these cardiac complications. This study demonstrated USCOM was cost-effective for detecting these changes and useful for monitoring these patients.

Executive Chairman of Uscom, Rob Phillips said, “Improving treatment of cancer is a massive community responsibility. Accurate monitoring of the heart function of cancer patients during cancer treatment is critical, and this study confirms that USCOM provides a simple cost-effective solution which may lead to improved outcomes. This is further evidence of the platform nature of the USCOM technology and confirms the potentially community wide usefulness of USCOM monitoring.”

Reference:

Geiger S, Stemmler HJ, Suhl P, Stieber P, Lange V, Baur D, Hausmann A, Tischer j, Horster S. Anthracycline-Induced Cardiotoxicity: Cardiac Monitoring by Continuous Wave-Doppler Ultrasound Cardiac Output Monitoring and Correlation to Echocardiography. Onkologie 2012;35:241-246 (DOI:10.1159/000338335

About Uscom

Uscom Limited is an Australian medical device company which listed on the Australian Stock Exchange in December 2003. Uscom has developed a Non Invasive Cardiac Output Monitor. The USCOM is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency and Intensive Care Medicine and Anesthesia, and is a tool of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

USCOM has global regulatory approval and the device is currently marketed in North America, South America, Europe, the Middle East, Australia & New Zealand, China and SE Asia.

Uscom Contacts Rob Phillips Executive Chairman rob@uscom.com.au

Tom Rowe Company Secretary secretary@uscom.com.au